60 Degrees Pharmaceuticals (SXTP) Competitors $1.26 -0.04 (-3.08%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.28 +0.02 (+1.59%) As of 08/22/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock SXTP vs. OBSV, AEON, GNPX, NLSP, BMRA, KPRX, MTNB, MBIO, APM, and EVOKShould you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include ObsEva (OBSV), AEON Biopharma (AEON), Genprex (GNPX), NLS Pharmaceutics (NLSP), Biomerica (BMRA), Kiora Pharmaceuticals (KPRX), Matinas Biopharma (MTNB), Mustang Bio (MBIO), Aptorum Group (APM), and Evoke Pharma (EVOK). These companies are all part of the "pharmaceutical products" industry. 60 Degrees Pharmaceuticals vs. Its Competitors ObsEva AEON Biopharma Genprex NLS Pharmaceutics Biomerica Kiora Pharmaceuticals Matinas Biopharma Mustang Bio Aptorum Group Evoke Pharma ObsEva (NASDAQ:OBSV) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation. Do institutionals & insiders believe in OBSV or SXTP? 17.5% of ObsEva shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 14.4% of ObsEva shares are owned by company insiders. Comparatively, 10.3% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer OBSV or SXTP? In the previous week, 60 Degrees Pharmaceuticals had 3 more articles in the media than ObsEva. MarketBeat recorded 3 mentions for 60 Degrees Pharmaceuticals and 0 mentions for ObsEva. ObsEva's average media sentiment score of 0.00 equaled 60 Degrees Pharmaceuticals'average media sentiment score. Company Overall Sentiment ObsEva Neutral 60 Degrees Pharmaceuticals Neutral Do analysts recommend OBSV or SXTP? 60 Degrees Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 455.56%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than ObsEva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.0060 Degrees Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, OBSV or SXTP? ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.71, suggesting that its share price is 171% more volatile than the S&P 500. Is OBSV or SXTP more profitable? ObsEva has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -976.86%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets ObsEvaN/A -416.36% -92.01% 60 Degrees Pharmaceuticals -976.86%N/A -133.88% Which has better earnings & valuation, OBSV or SXTP? 60 Degrees Pharmaceuticals has higher revenue and earnings than ObsEva. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObsEvaN/AN/A-$58.38M-$0.92N/A60 Degrees Pharmaceuticals$300K17.22-$7.95M-$50.41-0.02 Summary60 Degrees Pharmaceuticals beats ObsEva on 8 of the 14 factors compared between the two stocks. Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTP vs. The Competition Export to ExcelMetric60 Degrees PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.34M$2.57B$5.76B$9.58BDividend YieldN/A1.67%4.41%4.10%P/E Ratio-0.0222.6131.1026.04Price / Sales17.22554.26433.45102.77Price / CashN/A180.4637.7358.48Price / Book-0.725.939.536.61Net Income-$7.95M$31.83M$3.26B$265.56M7 Day Performance-4.55%1.89%2.10%1.97%1 Month Performance-5.97%1.33%2.81%-0.36%1 Year Performance-86.08%8.84%30.56%19.03% 60 Degrees Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTP60 Degrees Pharmaceuticals2.3906 of 5 stars$1.26-3.1%$7.00+455.6%-86.9%$5.34M$300K-0.023News CoverageShort Interest ↓OBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050Gap DownAEONAEON Biopharma2.9126 of 5 stars$0.69+5.0%$360.00+52,134.5%-98.9%$7.79MN/A3.835Gap DownGNPXGenprex1.6224 of 5 stars$0.23+10.2%N/A-76.0%$7.77MN/A0.0020Gap UpNLSPNLS PharmaceuticsN/A$2.12+1.9%N/A+1,379.2%$7.63MN/A0.006Short Interest ↓BMRABiomerica0.5008 of 5 stars$2.99-0.7%N/A-0.1%$7.63M$5.41M-1.2960Positive NewsUpcoming EarningsShort Interest ↓KPRXKiora Pharmaceuticals2.7814 of 5 stars$2.50+2.0%$10.00+300.0%-26.2%$7.60M$16.02M-0.8610Gap UpMTNBMatinas Biopharma0.7235 of 5 stars$1.48-7.5%N/AN/A$7.53MN/A-0.3130MBIOMustang Bio0.4698 of 5 stars$1.70-3.4%N/A-91.3%$7.45MN/A-0.02100Positive NewsGap DownAPMAptorum Group0.7511 of 5 stars$1.39-2.1%N/A-12.6%$7.44M$430K0.0030News CoverageGap DownEVOKEvoke Pharma0.6109 of 5 stars$4.99-8.8%N/A+24.8%$7.44M$10.25M-1.744Gap Down Related Companies and Tools Related Companies OBSV Competitors AEON Competitors GNPX Competitors NLSP Competitors BMRA Competitors KPRX Competitors MTNB Competitors MBIO Competitors APM Competitors EVOK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SXTP) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access